Test Price
3,000 AED✅ Home Collection Available
Comprehensive Ophthalmic Genetic Disorder Panel in UAE | 3000 AED | 2026 DHA Guidelines
تحليل لوحة الاضطرابات الجينية العينية الشامل في الإمارات | 3000 درهم | معتمد من هيئة الصحة بدبي
Executive Summary & Clinical Guarantee
ملخص تنفيذي: يقدم هذا التحليل الجيني الشامل أعلى دقة تشخيصية بنسبة 99.9% لأمراض العيون الوراثية عبر تقنية التسلسل الجيني المتقدم، مع خدمة سحب منزلي متميزة معتمدة من الهيئة وفق أحدث مراسيم القانون الاتحادي لدولة الإمارات لعام 2026.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139) and Next Generation Sequencing (NGS) methodology.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy — adhering strictly to UAE PDPL data privacy and specimen integrity protocols from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by a DHA-licensed expert to correlate genetic findings with your broader ophthalmologic profile.
- Insurance & Support: Direct Billing Verification and immediate pre-test consultation via WhatsApp at +971 54 548 8731.
Overview: Why This Comprehensive Panel Matters
The Comprehensive Ophthalmic Genetic Disorder Panel analyzes over 500 genes associated with inherited retinal dystrophies, optic neuropathies, congenital cataracts, and anterior segment dysgenesis, providing a definitive molecular diagnosis where clinical presentation overlaps. This single blood test replaces sequential single-gene testing, streamlining the diagnostic odyssey for UAE families affected by vision loss.
| Feature | Our Test (Premium) | Closest Alternative |
|---|---|---|
| Precision & Depth | Full Gene sequencing via NGS with deletion/duplication analysis (CNV detection). >99.9% analytical sensitivity. | Targeted mutation panels or single-gene Sanger sequencing. Limited variant detection. |
| Methodology | Next Generation Sequencing (NGS) aligned to 2026 AI-augmented genome datasets. | Microarray or older genotyping arrays, often missing rare variants. |
| Turnaround Time | 21 Working Days, expedited clinical reporting portal access. | Often 8-12 weeks for multi-step reflex testing to reference labs abroad. |
| Report Actionability | Includes ICD-10-coded diagnosis, genetic counseling notes, and therapeutic trial eligibility. | Limited to variant description without clinical correlation or therapeutic mapping. |
Physician Insight & Patient Safety Protocol
"As an Ophthalmologist, I view this panel as a crucial compass. A positive result not only confirms the clinical suspicion but also opens doors to gene-specific therapies and precise family planning. However, a negative result does not rule out a genetic etiology; it must be correlated with the full clinical picture, including electroretinography and detailed slit-lamp examination, to guide the next step in your care plan."
— Dr. PRABHAKAR REDDY, DHA License No: 61713011
Critical Medication Warning
Do not discontinue prescribed ocular or systemic medication without consulting your doctor. Genetic results are not an immediate directive for treatment change and require specialist integration with your current therapeutic regimen.
Safety Exclusion & Emergency Red Flags
- Exclusion Criteria: This test cannot be processed for patients who have undergone allogeneic bone marrow transplantation within the last 6 months, as donor DNA will confound germline results. Active severe leukopenia contraindicating phlebotomy is an absolute exclusion.
- Post-Test Red Flags: If you experience sudden irreversible vision loss, severe eye pain, or symptoms of retinal detachment before or after testing, do not wait for results. Proceed immediately to the nearest emergency department.
Patient FAQ & Clinical Guidance
Q: Does this panel screen for all causes of childhood blindness in the UAE population?
This Comprehensive Ophthalmic Panel screens for over 500 genes, providing a 92% first-pass diagnostic yield for inherited retinal diseases common in consanguineous populations such as Leber Congenital Amaurosis and Retinitis Pigmentosa, but it does not cover non-genetic prenatal infections.
س: هل تفحص هذه اللوحة جميع أسباب العمى الوراثي لدى الأطفال في دولة الإمارات؟ ج: تغطي هذه اللوحة الشاملة أكثر من 500 جين، مما يوفر عائد تشخيصي أولي بنسبة 92٪ لأمراض الشبكية الوراثية الشائعة في المجتمعات ذات صلة القرابة.
Q: What is the exact home collection protocol for a DNA FTA card in Dubai?
A DHA-licensed phlebotomist arrives at your home between 8 AM and 11 PM and performs a simple, nearly painless finger-prick collection, depositing blood spots directly onto a DNA-stabilizing FTA card for immediate room-temperature storage, in full compliance with Federal Decree-Law No. 41 of 2024.
س: ما هي بروتوكولات السحب المنزلي لبطاقة FTA للحمض النووي في دبي؟ ج: يصل أخصائي سحب دم مرخص من هيئة الصحة بدبي إلى منزلك لإجراء وخز إصبع بسيط، وتودع بقع الدم على بطاقة FTA لحفظ الحمض النووي، وفقاً للمرسوم بقانون اتحادي رقم 41 لعام 2024.
Q: Could a negative result on this NGS mean my eye disease is still genetic?
Yes, a negative NGS result cannot exclude pathogenic deep intronic variants, mitochondrial heteroplasmy below the detection threshold, or complex structural rearrangements, necessitating potential whole genome sequencing if clinical suspicion remains high.
س: هل يعني ظهور نتيجة سلبية في اختبار التسلسل الجيني أن مرضي العيني ليس وراثياً؟ ج: لا، فالنتيجة السلبية لا تستبعد الطفرات العميقة داخل الإنترونات أو إعادة الترتيب الهيكلي المعقد، وقد يستدعي الأمر تسلسل الجينوم الكامل لاحقاً.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians